Mendus has presented incremental clinical data for vididencel at the American Society of Hematology (ASH) 67th Annual Meeting, involving long-term follow-up for the ADVANCE II trial. This study is testing the ability of the candidate to prolong survival in acute myeloid leukaemia (AML) as a mainten
